Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
|Cell lines||Swiss 3T3|
|Preparation method||Seeding cells in 24-well plates (5000 cells/well) in DMEM/10% FCS. A day later, the medium is changed to DMEM/2% FcS with or without growth factors and tyrphostins are added as indicated. Three days later count the cells in a hemocytometer|
|Incubation time||3 days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Oncol Lett (2015). Figure 2. Tyrphostin AG 1296|
|Method||cell invasion assay|
|Cell Lines||U87MG cells|
|Concentrations||12.5, 50 or 200 nM|
|Incubation Time||8 h|
|Results||Statistical analysis demonstrated that the anti.migration effect of tyrphostin AG 1296 in U87MG cells, increased in a dose.dependent manner|
|Related VEGFR/PDGFR Products|
Avitinib maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (EGFR) inhibitor with an IC50 of 7.68 nM.
Fruquintinib (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively.
SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.
Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret.
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.